DE60128902D1 - Formulierungen zur verwendung in inhalationsvorrichtungen - Google Patents

Formulierungen zur verwendung in inhalationsvorrichtungen

Info

Publication number
DE60128902D1
DE60128902D1 DE60128902T DE60128902T DE60128902D1 DE 60128902 D1 DE60128902 D1 DE 60128902D1 DE 60128902 T DE60128902 T DE 60128902T DE 60128902 T DE60128902 T DE 60128902T DE 60128902 D1 DE60128902 D1 DE 60128902D1
Authority
DE
Germany
Prior art keywords
formulations
diameter
inhalation devices
formulation
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128902T
Other languages
English (en)
Other versions
DE60128902T2 (de
Inventor
John Nicholas Staniforth
David Alexander Vodden Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60128902(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009468.0A external-priority patent/GB0009468D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of DE60128902D1 publication Critical patent/DE60128902D1/de
Application granted granted Critical
Publication of DE60128902T2 publication Critical patent/DE60128902T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60128902T 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen Expired - Lifetime DE60128902T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0009468.0A GB0009468D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formulations for use in inhaler devices
GB0009468 2000-04-17
EP00113608 2000-06-27
EP00113608 2000-06-27
PCT/GB2001/001757 WO2001078696A2 (en) 2000-04-17 2001-04-17 Formulations for use in inhaler devices

Publications (2)

Publication Number Publication Date
DE60128902D1 true DE60128902D1 (de) 2007-07-26
DE60128902T2 DE60128902T2 (de) 2008-02-14

Family

ID=26071083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128902T Expired - Lifetime DE60128902T2 (de) 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen

Country Status (9)

Country Link
EP (1) EP1276474B1 (de)
JP (1) JP2004500424A (de)
AT (1) ATE364381T1 (de)
AU (1) AU782841B2 (de)
CA (1) CA2406206C (de)
DE (1) DE60128902T2 (de)
ES (1) ES2288167T3 (de)
NZ (1) NZ521972A (de)
WO (1) WO2001078696A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
ATE301990T1 (de) 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
CA2693377A1 (en) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
EP2240481A1 (de) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinon)-substituierte pyridoindole als mch-antagonisten
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TWI491416B (zh) 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
BRPI1007350B8 (pt) 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
WO2010107964A1 (en) * 2009-03-18 2010-09-23 Pleiades Cardio-Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP6185648B2 (ja) 2013-03-15 2017-08-23 スリーディー システムズ インコーポレーテッド ３次元印刷用材料系
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
IL260335B2 (en) 2016-02-01 2023-10-01 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3768378A4 (de) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. Neuartiges verfahren zur verlangsamung der ventrikulären rate
KR20210042412A (ko) 2018-09-06 2021-04-19 주식회사 이노파마스크린 천식 또는 파킨슨병 치료를 위한 방법 및 조성물
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation

Also Published As

Publication number Publication date
EP1276474A2 (de) 2003-01-22
AU4860101A (en) 2001-10-30
ATE364381T1 (de) 2007-07-15
WO2001078696A2 (en) 2001-10-25
CA2406206C (en) 2012-03-20
EP1276474B1 (de) 2007-06-13
JP2004500424A (ja) 2004-01-08
WO2001078696A3 (en) 2002-03-14
ES2288167T3 (es) 2008-01-01
DE60128902T2 (de) 2008-02-14
NZ521972A (en) 2004-06-25
AU782841B2 (en) 2005-09-01
CA2406206A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
DE60128902D1 (de) Formulierungen zur verwendung in inhalationsvorrichtungen
MXPA02010213A (es) Mejoras en, o relacionadas con formulaciones para usarse en aparatos inhiladores.
ATE271383T1 (de) Pulverformulierung zur inhalation
CY1107350T1 (el) Εισπνευστηρας ξηρης σκονης πολλαπλων δοσεων με δεξαμενη σκονης
MY119074A (en) Pharmaceutical aerosol composition
EE9700176A (et) Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine
IT1303788B1 (it) Formulazioni di aerosol medicinali.
CA2370853A1 (en) Compositions for aerosolization and inhalation
EP1348428A4 (de) Pulverzubereitungen und verfahren zu ihrer herstellung
SE9700135D0 (sv) New formulation
DK0871430T4 (da) Pulvere og anvendelse til i törpulverinhalatorer
WO2001036015A3 (en) Powder inhaler
AU2001284072A1 (en) A device for determining the size distribution of aerosol particles
ATE239456T1 (de) Pharmazeutische formulierung in form eines trockenen pulvers
ATE424186T1 (de) Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
NZ513981A (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
UY26653A1 (es) Producto sólido blando estable y eficaz

Legal Events

Date Code Title Description
8363 Opposition against the patent